Impact Factor
3.23
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.83
1,074 total citations
h5-index
31
h5 depth signal
Cited share
63.7%
390 of 612
Total citations
1,074
Citation footprint
Metric signal
1.81
External metric anchor
Self-citation
3.1%
33 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,930
China
442
Italy
300
Germany
279
France
266
Citing Fields of Research
Lymphomas
2,310
Hematology
2,256
Oncology
514
Immunology
410
Palliative Care
218
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
14,242
Articles tracked across the journal lifetime
Indexed publication set
612
390 cited publications
Last 12 months
364
30.3 publications/month
Open access share
16.5%
60 OA publications in the last year
Leading citing country
United States
1,930 citing publications
Leading citing field
Lymphomas
2,310 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v7n1, 1992-
v7n1, 1992-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Lymphomas
Broad Categories
Hematology
Neoplasms
Lymphomas
MeSH Descriptors
Leukemia
Lymphoma
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1080/10428194.2026.2745238
Open DOI
Immunoglobulin kinetics and infection patterns across venetoclax-based regimens in chronic lymphocytic leukemia
03
DOI 10.1080/10428194.2026.2747547
Open DOI
Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports
04
DOI 10.1080/10428194.2026.2746186
Open DOI
Long-term mental health service utilization among patients with diffuse large B-cell lymphoma: a population-based study
05
DOI 10.1080/10428194.2026.2743355
Open DOI
Emerging drug profile: bexobrutideg
06
DOI 10.1080/10428194.2026.2742608
Open DOI
Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, and intensive chemotherapy has long been the standard of care for patients fit enough to receive it [1]. For older or comor...
07
DOI 10.1080/10428194.2026.2739358
Open DOI
Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies
Myelofibrosis (MF) is a myeloproliferative neoplasm with a significant negative impact on patient quality of life and survival [1–4]. MF is characterized by bone marrow fibrosis, splenomegaly, cyto...
08
DOI 10.1080/10428194.2026.2738355
Open DOI
Delayed platelet recovery in lymphoma patients after autologous hematopoietic cell transplantation – risk factors and prognostic significance
A higher graft CD34+ cell count is associated with higher platelet (PLT) counts after autologous hematopoietic cell transplantation (AHCT) in lymphoma patients both in the short- and long-term [1–5...
09
DOI 10.1080/10428194.2026.2741486
Open DOI
Evaluating YouTube videos for Hodgkin lymphoma patient education
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
19921229 Not printed on acid-free paper